Quince Therapeutics (NASDAQ:QNCX) Given New $4.00 Price Target at D. Boral Capital

Quince Therapeutics (NASDAQ:QNCX) had its price objective reduced by equities researchers at D. Boral Capital from $12.00 to $4.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. D. Boral Capital’s price objective suggests a potential upside of 185.71% from the company’s current price.

QNCX has been the topic of several other research reports. Oppenheimer initiated coverage on shares of Quince Therapeutics in a report on Monday. They set an “outperform” rating and a $10.00 price objective on the stock. Brookline Capital Management began coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Quince Therapeutics currently has an average rating of “Buy” and a consensus target price of $8.00.

Quince Therapeutics Stock Up 1.4 %

NASDAQ:QNCX opened at $1.40 on Tuesday. The company’s 50-day simple moving average is $1.49 and its 200-day simple moving average is $1.44. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The stock has a market capitalization of $61.60 million, a P/E ratio of -1.13 and a beta of 0.71.

Quince Therapeutics (NASDAQ:QNCX) last announced its earnings results on Monday, March 24th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The business had revenue of $0.17 million for the quarter. On average, equities analysts anticipate that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Quince Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of QNCX. Geode Capital Management LLC lifted its stake in Quince Therapeutics by 10.9% during the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock valued at $703,000 after acquiring an additional 36,807 shares during the period. Shay Capital LLC raised its holdings in shares of Quince Therapeutics by 60.8% during the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock worth $518,000 after purchasing an additional 104,616 shares during the last quarter. Scharf Investments LLC acquired a new position in Quince Therapeutics during the fourth quarter valued at $170,000. Northern Trust Corp lifted its position in Quince Therapeutics by 48.5% during the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after purchasing an additional 16,501 shares during the period. Finally, Two Sigma Investments LP purchased a new stake in Quince Therapeutics in the fourth quarter valued at $57,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.